NCT02480686View on ClinicalTrials.gov

Neutrino Regimen for Treatment-experienced HCV GT1 Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Chronic Hepatitis C Infection
Interventions
DRUG

SOF+PEG+RBV

Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).

Trial Locations (2)

100039

Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital, Beijing

00852

Humanity and Health GI and Liver Centre, Hong Kong

All Listed Sponsors
collaborator

Beijing 302 Hospital

OTHER

lead

Humanity and Health Research Centre

OTHER

NCT02480686 - Neutrino Regimen for Treatment-experienced HCV GT1 Patients | Biotech Hunter | Biotech Hunter